New drug combo aims to fight lung cancer after chemoradiation
NCT ID NCT07091305
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the drug QL1706 to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. QL1706 is a type of immunotherapy that targets two immune checkpoints to help the body fight cancer. The study will enroll 28 participants and measure how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (a drug that targets two immune checkpoints, PD-1 and CTLA-4)
- What this could lead to
- If successful, this could offer a new treatment option that improves how long people with limited-stage small cell lung cancer live without their cancer getting worse.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The drug combination can cause serious immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a double immune attack keep lung cancer at bay?
- Kidney transplant trial tests which drug better prevents rejection
- Brain tumor patients with severe symptoms may get a new treatment option
- Gut check: could sauerkraut and fiber help fight cancer?
- New drug combo aims to keep lung cancer at bay longer